Global Retinal Biologics Market

Retinal Biologics Comprehensive Study by Application (Hospitals, Clinics, Research Organizations, Others), Diagnostic Tests (Amsler grid test, Optical coherence tomography (OCT), Fundus autofluorescence (FAF), Others), Disease Indication (Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Epiretinal Membrane, Macular Hole, Other) Players and Region - Global Market Outlook to 2030

Retinal Biologics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Retinal Biologics
Biologics are effective medicines made up of small components such as sugars, proteins, or DNA, or entire cells or tissues. Retinal biologics are bioengineered particles implanted in the eyes to treat chronic retinal diseases. The majority of biologics are derived from living organisms, such as plant or animal cells or microorganisms. Macugen, Humira, Lucentis, Eylea, and other retinal biologics are used to treat retinal diseases. With the increase in diabetes across the world; the demand for retinal biologics is also increasing.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The future of the retinal biologics market is bright, with continued research and development promising even more effective and accessible treatments. As competition intensifies and innovation thrives, the landscape is likely to see further consolidation, partnerships, and breakthroughs, ultimately leading to improved vision and quality of life for millions suffering from retinal diseases. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Spark Therapeutics (United States), Regeneron Pharmaceuticals, Inc. (United States), AbbVie Inc. (United States), Johnson & Johnson (United States), Amgen Inc. (United States), Novartis International AG (Switzerland) and ALLERGAN (Ireland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Janssen Biotech (United States), Ocular Therapeutix (United States), Samsung Biologics (South Korea) and Spark Therapeutics (United States).

Segmentation Overview
AMA Research has segmented the market of Global Retinal Biologics market by , Application (Hospitals, Clinics, Research Organizations and Others) and Region.



On the basis of geography, the market of Retinal Biologics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnostic Tests, the sub-segment i.e. Amsler grid test will boost the Retinal Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indication, the sub-segment i.e. Retinal Tear will boost the Retinal Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in Technology of Retinal Biologics

Market Growth Drivers:
Need of Retinal Biologics to Treat Retinal Diseases and Growing Diabetic Population

Challenges:
Need of High R&D Expenses for The Development of Retinal Biologics and Lack of Enough Skilled Employees to Operate in Manufacture of Retinal Biologics

Restraints:
High Cost Associated with Retinal Biologics

Opportunities:
Increasing Awareness About the Retinal Disease Will Boost the Demand of Retinal Biologics and Growing Investment in Medical Infrastructure by Developing Countries Will Increase the Demand of Retinal Biologics

Market Leaders and their expansionary development strategies

In December 2023, Gyroscope Therapeutics receives FDA Fast Track designation for GB-601. This potential gene therapy for choroideremia, a progressive X-linked retinal disease, aims to restore vision by introducing a functional copy of the REP1 gene.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Retinal Biologics Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Research Organizations
  • Others
By Diagnostic Tests
  • Amsler grid test
  • Optical coherence tomography (OCT)
  • Fundus autofluorescence (FAF)
  • Others

By Disease Indication
  • Retinal Tear
  • Retinal Detachment
  • Diabetic Retinopathy
  • Epiretinal Membrane
  • Macular Hole
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Need of Retinal Biologics to Treat Retinal Diseases
      • 3.2.2. Growing Diabetic Population
    • 3.3. Market Challenges
      • 3.3.1. Need of High R&D Expenses for The Development of Retinal Biologics
      • 3.3.2. Lack of Enough Skilled Employees to Operate in Manufacture of Retinal Biologics
    • 3.4. Market Trends
      • 3.4.1. Advancements in Technology of Retinal Biologics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Retinal Biologics, by Application, Diagnostic Tests, Disease Indication and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Retinal Biologics (Value)
      • 5.2.1. Global Retinal Biologics by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Research Organizations
        • 5.2.1.4. Others
      • 5.2.2. Global Retinal Biologics by: Diagnostic Tests (Value)
        • 5.2.2.1. Amsler grid test
        • 5.2.2.2. Optical coherence tomography (OCT)
        • 5.2.2.3. Fundus autofluorescence (FAF)
        • 5.2.2.4. Others
      • 5.2.3. Global Retinal Biologics by: Disease Indication (Value)
        • 5.2.3.1. Retinal Tear
        • 5.2.3.2. Retinal Detachment
        • 5.2.3.3. Diabetic Retinopathy
        • 5.2.3.4. Epiretinal Membrane
        • 5.2.3.5. Macular Hole
        • 5.2.3.6. Other
      • 5.2.4. Global Retinal Biologics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Retinal Biologics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Spark Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ALLERGAN (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Retinal Biologics Sale, by Application, Diagnostic Tests, Disease Indication and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Retinal Biologics (Value)
      • 7.2.1. Global Retinal Biologics by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Research Organizations
        • 7.2.1.4. Others
      • 7.2.2. Global Retinal Biologics by: Diagnostic Tests (Value)
        • 7.2.2.1. Amsler grid test
        • 7.2.2.2. Optical coherence tomography (OCT)
        • 7.2.2.3. Fundus autofluorescence (FAF)
        • 7.2.2.4. Others
      • 7.2.3. Global Retinal Biologics by: Disease Indication (Value)
        • 7.2.3.1. Retinal Tear
        • 7.2.3.2. Retinal Detachment
        • 7.2.3.3. Diabetic Retinopathy
        • 7.2.3.4. Epiretinal Membrane
        • 7.2.3.5. Macular Hole
        • 7.2.3.6. Other
      • 7.2.4. Global Retinal Biologics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Retinal Biologics: by Application(USD Million)
  • Table 2. Retinal Biologics Hospitals , by Region USD Million (2018-2023)
  • Table 3. Retinal Biologics Clinics , by Region USD Million (2018-2023)
  • Table 4. Retinal Biologics Research Organizations , by Region USD Million (2018-2023)
  • Table 5. Retinal Biologics Others , by Region USD Million (2018-2023)
  • Table 6. Retinal Biologics: by Diagnostic Tests(USD Million)
  • Table 7. Retinal Biologics Amsler grid test , by Region USD Million (2018-2023)
  • Table 8. Retinal Biologics Optical coherence tomography (OCT) , by Region USD Million (2018-2023)
  • Table 9. Retinal Biologics Fundus autofluorescence (FAF) , by Region USD Million (2018-2023)
  • Table 10. Retinal Biologics Others , by Region USD Million (2018-2023)
  • Table 11. Retinal Biologics: by Disease Indication(USD Million)
  • Table 12. Retinal Biologics Retinal Tear , by Region USD Million (2018-2023)
  • Table 13. Retinal Biologics Retinal Detachment , by Region USD Million (2018-2023)
  • Table 14. Retinal Biologics Diabetic Retinopathy , by Region USD Million (2018-2023)
  • Table 15. Retinal Biologics Epiretinal Membrane , by Region USD Million (2018-2023)
  • Table 16. Retinal Biologics Macular Hole , by Region USD Million (2018-2023)
  • Table 17. Retinal Biologics Other , by Region USD Million (2018-2023)
  • Table 18. South America Retinal Biologics, by Country USD Million (2018-2023)
  • Table 19. South America Retinal Biologics, by Application USD Million (2018-2023)
  • Table 20. South America Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 21. South America Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 22. Brazil Retinal Biologics, by Application USD Million (2018-2023)
  • Table 23. Brazil Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 24. Brazil Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 25. Argentina Retinal Biologics, by Application USD Million (2018-2023)
  • Table 26. Argentina Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 27. Argentina Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 28. Rest of South America Retinal Biologics, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 30. Rest of South America Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 31. Asia Pacific Retinal Biologics, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Retinal Biologics, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 34. Asia Pacific Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 35. China Retinal Biologics, by Application USD Million (2018-2023)
  • Table 36. China Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 37. China Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 38. Japan Retinal Biologics, by Application USD Million (2018-2023)
  • Table 39. Japan Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 40. Japan Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 41. India Retinal Biologics, by Application USD Million (2018-2023)
  • Table 42. India Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 43. India Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 44. South Korea Retinal Biologics, by Application USD Million (2018-2023)
  • Table 45. South Korea Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 46. South Korea Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 47. Taiwan Retinal Biologics, by Application USD Million (2018-2023)
  • Table 48. Taiwan Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 49. Taiwan Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 50. Australia Retinal Biologics, by Application USD Million (2018-2023)
  • Table 51. Australia Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 52. Australia Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Retinal Biologics, by Application USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 56. Europe Retinal Biologics, by Country USD Million (2018-2023)
  • Table 57. Europe Retinal Biologics, by Application USD Million (2018-2023)
  • Table 58. Europe Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 59. Europe Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 60. Germany Retinal Biologics, by Application USD Million (2018-2023)
  • Table 61. Germany Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 62. Germany Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 63. France Retinal Biologics, by Application USD Million (2018-2023)
  • Table 64. France Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 65. France Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 66. Italy Retinal Biologics, by Application USD Million (2018-2023)
  • Table 67. Italy Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 68. Italy Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 69. United Kingdom Retinal Biologics, by Application USD Million (2018-2023)
  • Table 70. United Kingdom Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 71. United Kingdom Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 72. Netherlands Retinal Biologics, by Application USD Million (2018-2023)
  • Table 73. Netherlands Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 74. Netherlands Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 75. Rest of Europe Retinal Biologics, by Application USD Million (2018-2023)
  • Table 76. Rest of Europe Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 77. Rest of Europe Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 78. MEA Retinal Biologics, by Country USD Million (2018-2023)
  • Table 79. MEA Retinal Biologics, by Application USD Million (2018-2023)
  • Table 80. MEA Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 81. MEA Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 82. Middle East Retinal Biologics, by Application USD Million (2018-2023)
  • Table 83. Middle East Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 84. Middle East Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 85. Africa Retinal Biologics, by Application USD Million (2018-2023)
  • Table 86. Africa Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 87. Africa Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 88. North America Retinal Biologics, by Country USD Million (2018-2023)
  • Table 89. North America Retinal Biologics, by Application USD Million (2018-2023)
  • Table 90. North America Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 91. North America Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 92. United States Retinal Biologics, by Application USD Million (2018-2023)
  • Table 93. United States Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 94. United States Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 95. Canada Retinal Biologics, by Application USD Million (2018-2023)
  • Table 96. Canada Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 97. Canada Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 98. Mexico Retinal Biologics, by Application USD Million (2018-2023)
  • Table 99. Mexico Retinal Biologics, by Diagnostic Tests USD Million (2018-2023)
  • Table 100. Mexico Retinal Biologics, by Disease Indication USD Million (2018-2023)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Retinal Biologics: by Application(USD Million)
  • Table 109. Retinal Biologics Hospitals , by Region USD Million (2025-2030)
  • Table 110. Retinal Biologics Clinics , by Region USD Million (2025-2030)
  • Table 111. Retinal Biologics Research Organizations , by Region USD Million (2025-2030)
  • Table 112. Retinal Biologics Others , by Region USD Million (2025-2030)
  • Table 113. Retinal Biologics: by Diagnostic Tests(USD Million)
  • Table 114. Retinal Biologics Amsler grid test , by Region USD Million (2025-2030)
  • Table 115. Retinal Biologics Optical coherence tomography (OCT) , by Region USD Million (2025-2030)
  • Table 116. Retinal Biologics Fundus autofluorescence (FAF) , by Region USD Million (2025-2030)
  • Table 117. Retinal Biologics Others , by Region USD Million (2025-2030)
  • Table 118. Retinal Biologics: by Disease Indication(USD Million)
  • Table 119. Retinal Biologics Retinal Tear , by Region USD Million (2025-2030)
  • Table 120. Retinal Biologics Retinal Detachment , by Region USD Million (2025-2030)
  • Table 121. Retinal Biologics Diabetic Retinopathy , by Region USD Million (2025-2030)
  • Table 122. Retinal Biologics Epiretinal Membrane , by Region USD Million (2025-2030)
  • Table 123. Retinal Biologics Macular Hole , by Region USD Million (2025-2030)
  • Table 124. Retinal Biologics Other , by Region USD Million (2025-2030)
  • Table 125. South America Retinal Biologics, by Country USD Million (2025-2030)
  • Table 126. South America Retinal Biologics, by Application USD Million (2025-2030)
  • Table 127. South America Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 128. South America Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 129. Brazil Retinal Biologics, by Application USD Million (2025-2030)
  • Table 130. Brazil Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 131. Brazil Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 132. Argentina Retinal Biologics, by Application USD Million (2025-2030)
  • Table 133. Argentina Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 134. Argentina Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 135. Rest of South America Retinal Biologics, by Application USD Million (2025-2030)
  • Table 136. Rest of South America Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 137. Rest of South America Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 138. Asia Pacific Retinal Biologics, by Country USD Million (2025-2030)
  • Table 139. Asia Pacific Retinal Biologics, by Application USD Million (2025-2030)
  • Table 140. Asia Pacific Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 141. Asia Pacific Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 142. China Retinal Biologics, by Application USD Million (2025-2030)
  • Table 143. China Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 144. China Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 145. Japan Retinal Biologics, by Application USD Million (2025-2030)
  • Table 146. Japan Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 147. Japan Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 148. India Retinal Biologics, by Application USD Million (2025-2030)
  • Table 149. India Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 150. India Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 151. South Korea Retinal Biologics, by Application USD Million (2025-2030)
  • Table 152. South Korea Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 153. South Korea Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 154. Taiwan Retinal Biologics, by Application USD Million (2025-2030)
  • Table 155. Taiwan Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 156. Taiwan Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 157. Australia Retinal Biologics, by Application USD Million (2025-2030)
  • Table 158. Australia Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 159. Australia Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Retinal Biologics, by Application USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 163. Europe Retinal Biologics, by Country USD Million (2025-2030)
  • Table 164. Europe Retinal Biologics, by Application USD Million (2025-2030)
  • Table 165. Europe Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 166. Europe Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 167. Germany Retinal Biologics, by Application USD Million (2025-2030)
  • Table 168. Germany Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 169. Germany Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 170. France Retinal Biologics, by Application USD Million (2025-2030)
  • Table 171. France Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 172. France Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 173. Italy Retinal Biologics, by Application USD Million (2025-2030)
  • Table 174. Italy Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 175. Italy Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 176. United Kingdom Retinal Biologics, by Application USD Million (2025-2030)
  • Table 177. United Kingdom Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 178. United Kingdom Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 179. Netherlands Retinal Biologics, by Application USD Million (2025-2030)
  • Table 180. Netherlands Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 181. Netherlands Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 182. Rest of Europe Retinal Biologics, by Application USD Million (2025-2030)
  • Table 183. Rest of Europe Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 184. Rest of Europe Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 185. MEA Retinal Biologics, by Country USD Million (2025-2030)
  • Table 186. MEA Retinal Biologics, by Application USD Million (2025-2030)
  • Table 187. MEA Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 188. MEA Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 189. Middle East Retinal Biologics, by Application USD Million (2025-2030)
  • Table 190. Middle East Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 191. Middle East Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 192. Africa Retinal Biologics, by Application USD Million (2025-2030)
  • Table 193. Africa Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 194. Africa Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 195. North America Retinal Biologics, by Country USD Million (2025-2030)
  • Table 196. North America Retinal Biologics, by Application USD Million (2025-2030)
  • Table 197. North America Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 198. North America Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 199. United States Retinal Biologics, by Application USD Million (2025-2030)
  • Table 200. United States Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 201. United States Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 202. Canada Retinal Biologics, by Application USD Million (2025-2030)
  • Table 203. Canada Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 204. Canada Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 205. Mexico Retinal Biologics, by Application USD Million (2025-2030)
  • Table 206. Mexico Retinal Biologics, by Diagnostic Tests USD Million (2025-2030)
  • Table 207. Mexico Retinal Biologics, by Disease Indication USD Million (2025-2030)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Retinal Biologics: by Application USD Million (2018-2023)
  • Figure 5. Global Retinal Biologics: by Diagnostic Tests USD Million (2018-2023)
  • Figure 6. Global Retinal Biologics: by Disease Indication USD Million (2018-2023)
  • Figure 7. South America Retinal Biologics Share (%), by Country
  • Figure 8. Asia Pacific Retinal Biologics Share (%), by Country
  • Figure 9. Europe Retinal Biologics Share (%), by Country
  • Figure 10. MEA Retinal Biologics Share (%), by Country
  • Figure 11. North America Retinal Biologics Share (%), by Country
  • Figure 12. Global Retinal Biologics share by Players 2023 (%)
  • Figure 13. Global Retinal Biologics share by Players (Top 3) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Spark Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 16. Spark Therapeutics (United States) Revenue: by Geography 2023
  • Figure 17. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 19. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 23. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. ALLERGAN (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. ALLERGAN (Ireland) Revenue: by Geography 2023
  • Figure 29. Global Retinal Biologics: by Application USD Million (2025-2030)
  • Figure 30. Global Retinal Biologics: by Diagnostic Tests USD Million (2025-2030)
  • Figure 31. Global Retinal Biologics: by Disease Indication USD Million (2025-2030)
  • Figure 32. South America Retinal Biologics Share (%), by Country
  • Figure 33. Asia Pacific Retinal Biologics Share (%), by Country
  • Figure 34. Europe Retinal Biologics Share (%), by Country
  • Figure 35. MEA Retinal Biologics Share (%), by Country
  • Figure 36. North America Retinal Biologics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Spark Therapeutics (United States)
  • Regeneron Pharmaceuticals, Inc. (United States)
  • AbbVie Inc. (United States)
  • Johnson & Johnson (United States)
  • Amgen Inc. (United States)
  • Novartis International AG (Switzerland)
  • ALLERGAN (Ireland)
Additional players considered in the study are as follows:
Janssen Biotech (United States) , Ocular Therapeutix (United States) , Samsung Biologics (South Korea) , Spark Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 206 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Retinal Biologics Market Quantitative research analysis
Global Retinal Biologics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Spark Therapeutics (United States), Regeneron Pharmaceuticals, Inc. (United States), AbbVie Inc. (United States), Johnson & Johnson (United States), Amgen Inc. (United States), Novartis International AG (Switzerland) and ALLERGAN (Ireland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in Technology of Retinal Biologics" is seen as one of major influencing trends for Retinal Biologics Market during projected period 2023-2030.
The Retinal Biologics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Retinal Biologics Market Report?

Have a Query? Click Here

Other Related Reports

Enteric Empty Capsules Comprehensive Study by Type (Gelatin Capsules (Pig Meat Gelatin, Bovine-Derived Gelatin.Bone Meal, and Other Gelatin Sources), Non-Gelatin Capsules (Hydroxypropyl Methylcellulo...
$ 3750
Mouth Ulcer Treatment Drug Comprehensive Study by Route of Administration (Oral, Topical), Drugs Class (Corticosteroid, Analgesic, Antibiotic, Anti-Inflammatory, Others), Distribution Channel (Hospit...
$ 3800
Alopecia Treatment Comprehensive Study by Type (Topical Drugs (Creams, Oils, Gels, Shampoo, Lotions, Foams), Oral Drugs, Injectable Drugs (Platelet-rich Plasma. Injections, Injectable Fillers), Hair ...
$ 3750
Sleep Disorders Comprehensive Study by Type (Mattresses and Pillows, Sleep Laboratories, Medications, Sleep Disorder Devices), Category (Insomnia, Hypersomnia, Sleep apnea, Sleep breathing disorders,...
$ 3750
Throat Lozenges Comprehensive Study by Type (Hard Candy Lozenges, Soft Lozenges, Compressed Lozenges), Application (Pharmacy, Convenience Store, Other), Composition (Pectin Composition, Zinc Gluconat...
$ 3650
Bone Putty Comprehensive Study by Application (Orthopedic Surgery, Dental Surgery), End-users (Hospitals, Ambulatory Surgical Centers, Clinics, Others) Players and Region - Global Market Outlook to 2...
$ 3500